Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Griffith

Showing results (681-690 of 715) with videos related to

Pageof 72
Sort By:
Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.
The Journal of Clinical Investigation|June 6, 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor functionPamela Wong, Jennifer A Foltz, Lily Chang, et al.
The American Journal of Cardiology|May 6, 2014
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)Harry P Selker, James E Udelson, Joseph M Massaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
American Journal of Human Genetics|October 25, 2022
Bi-allelic CAMSAP1 variants cause a clinically recognizable neuronal migration disorderReham Khalaf-Nazzal, James Fasham, Katherine A Inskeep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
JAMA|March 29, 2012
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trialHarry P Selker, Joni R Beshansky, Patricia R Sheehan, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Pageof 72

Showing results (681-690 of 715) with videos related to

Sort By:
Pageof 72
Cancer Cell|September 8, 2025
Large B cell lymphoma microenvironment archetype profilesXubin Li, Kartik Singhal, Qing Deng, et al.
The Journal of Clinical Investigation|June 6, 2023
T-BET and EOMES sustain mature human NK cell identity and antitumor functionPamela Wong, Jennifer A Foltz, Lily Chang, et al.
The American Journal of Cardiology|May 6, 2014
One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)Harry P Selker, James E Udelson, Joseph M Massaro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
American Journal of Human Genetics|October 25, 2022
Bi-allelic CAMSAP1 variants cause a clinically recognizable neuronal migration disorderReham Khalaf-Nazzal, James Fasham, Katherine A Inskeep, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
JAMA|March 29, 2012
Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trialHarry P Selker, Joni R Beshansky, Patricia R Sheehan, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Pageof 72